Welcome to our dedicated page for Vivani Medical SEC filings (Ticker: VANI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vivani Medical, Inc. (VANI) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including Current Reports on Form 8-K, Annual Reports on Form 10-K, and Quarterly Reports on Form 10-Q. Vivani is a Delaware-incorporated, Nasdaq-listed clinical-stage biopharmaceutical company developing NanoPortal™-based long-acting GLP-1 implants and, through its Cortigent subsidiary, neuromodulation devices for vision restoration and stroke recovery.
In its recent Form 8-K filings, Vivani has reported material events such as equity financings via private placements and a registered direct offering of common stock, including details on share purchase agreements, gross proceeds, and reliance on exemptions from registration under Regulation D. Other 8-Ks furnish press releases covering business updates, preliminary financial information, and clinical data from the LIBERATE-1 Phase 1 study of NPM-115 and preclinical results for NPM-139. The company also uses 8-Ks to describe its plans and key dates related to the proposed spin-off of Cortigent, Inc.
Vivani’s periodic reports, referenced in its news releases, include its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, which the company cites for more detailed risk factors and financial information. These filings discuss topics such as operating losses, research and development expenses, cash position, and the risks associated with developing and commercializing its product candidates.
On Stock Titan, users can review Vivani’s filings as they are made available from EDGAR and use AI-powered summaries to understand the significance of individual documents, from capital-raising agreements and clinical program updates to shareholder meeting results and Cortigent spin-off disclosures.
Vivani Medical (VANI) filed its Q3 2025 10-Q, reporting continued operating investment as it advances subdermal GLP-1 implant programs. Cash and cash equivalents were $2.6 million at September 30, 2025, down from $18.4 million at year-end, with total assets of $25.0 million and stockholders’ equity of $1.3 million. Net loss was $6.5 million for the quarter and $20.0 million year-to-date, driven by R&D and G&A expenses.
The company highlighted clinical and portfolio progress: LIBERATE-1, the first-in-human study of its NanoPortal technology, met primary objectives with a positive safety and tolerability profile, informing plans to prioritize NPM-139 (semaglutide implant). Vivani outlined plans to initiate a Phase 1 study for NPM-139 in the first half of 2026, pending regulatory clearance. To support operations, Vivani entered equity purchase agreements expected to bring $18.6 million between September 30, 2025 and July 15, 2026, and subsequently raised approximately $6.0 million in a private placement and $9.7 million gross in a registered direct offering in October. Shares outstanding were 72,952,235 as of November 12, 2025.
Vivani Medical, Inc. furnished an 8-K announcing a business update and third quarter 2025 financial results via a press release, and provided a corporate slide presentation. The materials were furnished under Items 2.02 and 7.01 on November 13, 2025 and are available as Exhibits 99.1 (press release) and 99.2 (slides).
The company noted these materials are not deemed “filed” under the Exchange Act. Vivani also posted the current slide deck to the Investors section of its website.
Vivani Medical (VANI) director and 10% owner Gregg G. Williams reported purchasing 3,703,703 shares of common stock on 10/27/2025 at $1.62 per share in a private sale transaction under a Share Purchase Agreement dated 10/26/2025. The transaction totaled $5,999,998.86.
Following the trade, Williams beneficially owned 26,150,015 shares, comprising 4,799,200 held directly and 21,350,815 held indirectly.
Vivani Medical (VANI) secured new capital through two equity transactions. The company completed a private placement of 3,703,703 common shares at $1.62 per share, generating approximately $6.0 million in gross proceeds. No warrants, discounts, or placement fees were involved.
Concurrently, Vivani entered a registered direct offering for 6,000,000 common shares, with gross proceeds of approximately $9.7 million, before a 7.0% placement fee and up to $125,000 of reimbursable expenses paid to ThinkEquity. Directors and officers agreed to 60-day lock-ups from the closing of the registered offering. The registered sale is being made under the company’s effective Form S-3 shelf via a prospectus and prospectus supplement.
Vivani Medical, Inc. launched a registered direct offering of 6,000,000 shares of common stock at $1.62 per share. The company expects gross proceeds of $9,720,000, placement agent fees of 7.0%, and estimates net proceeds of approximately $8.7 million from this offering, with closing expected on or about October 28, 2025 subject to customary conditions.
Concurrently, an entity affiliated with director Gregg Williams agreed to purchase 3,703,703 shares in a separate private placement at the same price, generating an estimated additional $5.9 million in net proceeds; this sale is not part of the registered offering and carries no underwriting discounts or commissions. Combined net proceeds are approximately $14.7 million. Shares outstanding are expected to be 72,952,235 after the offering and concurrent private placement. Proceeds will fund research and clinical development, working capital, capital expenditures, and general corporate purposes, with management indicating funding into 2027.
Vivani Medical (VANI) insider filed a Form 4 reporting open-market style private purchases. On 10/15/2025, the reporting person, a Director and 10% Owner, acquired 1,473,214 shares at $1.12 per share pursuant to a Share Purchase Agreement dated March 26, 2025, and 264,550 shares at $1.26 per share pursuant to a Share Purchase Agreement dated August 11, 2025.
Following these transactions, beneficial ownership stood at 17,647,112 shares held indirectly and 4,799,200 shares held directly, for a combined 22,446,312 shares with voting and dispositive power over all such shares.
Vivani Medical, Inc. reported that it has temporarily withdrawn the previously announced October 8, 2025 record date for the planned spin-off of its wholly owned subsidiary, Cortigent, Inc. The change was announced on October 3, 2025 and is attributed to delays arising from the current shutdown of the U.S. federal government.
Cortigent is developing brain implant devices using neuromodulation technology, and the spin-off remains proposed, but the timing of determining which shareholders would be eligible to receive shares is now on hold until a new record date is set.
Gregg Williams, a director and reported 10% owner of Vivani Medical, Inc. (VANI), purchased shares in two private transactions during 2025. On 03/26/2025 he bought 1,473,215 shares at $1.12 per share (gross $1,650,000.80). On 08/11/2025 he bought 595,238 shares at $1.26 per share (gross $749,999.88). Following the reported transactions dated 09/15/2025, the filing shows beneficial ownership totaling 20,708,548 shares, with a detailed breakdown across trusts and entities for which he has voting and dispositive power. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Vivani Medical, Inc. is moving forward with its previously announced spin-off of its wholly owned subsidiary, Cortigent, Inc., which develops brain implant devices using neuromodulation technology. The company has set October 8, 2025 as the record date for the transaction. Stockholders who hold Vivani common stock as of that date will be entitled to receive Cortigent common stock when the spin-off is completed. The company stated that the distribution date and the share dividend ratio for Cortigent stock will be announced at a later time. Vivani also issued a press release on September 17, 2025, describing this update.
Vivani Medical, Inc. filed a current report to furnish its latest corporate slide presentation to the investment community. The slide deck, dated September 9, 2025, is attached as Exhibit 99.1 and is also available in the Investors section of the company’s website.
The slides are provided under Regulation FD as investor information and are deemed “furnished,” not “filed,” which limits their use for certain securities law liability purposes. Vivani notes the slides speak only as of their date and expressly disclaims any obligation to update them.